Search Results for "amyloidosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Effect of Patisiran Treatment in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy: Post-hoc Analysis of the APOLLO-B Study

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study

Gene Silencing Therapeutics in Cardiology: A Review Article

Effects of Vutrisiran on Echocardiographic Cardiac Structure and Function: The HELIOS-B Trial

Phase 3 HELIOS-B Study Rationale

This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.

Long-term Effects of Patisiran on Survival and Cardiac Parameters in Patients with Transthyretin-mediated Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B and Cardiac Subpopulation of APOLLO OLE

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.